MANKIND.NS
Cash Flow
Mankind Pharma Ltd. · Healthcare
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-09-23 02:27
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹1,813.30 Cr. | ₹2,152.45 Cr. | ₹2,413.38 Cr. | ₹3,121.29 Cr. | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-1,054.13 Cr. | ₹-2,081.69 Cr. | ₹-12,682.95 Cr. | ₹-196.42 Cr. | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-739.73 Cr. | ₹5.27 Cr. | ₹10,290.13 Cr. | ₹-2,952.69 Cr. | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹2.32 Cr. | ₹1.17 Cr. | ₹1.31 Cr. | ₹15.63 Cr. | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹21.76 Cr. | ₹77.19 Cr. | ₹21.87 Cr. | ₹-12.19 Cr. | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹283.06 Cr. | ₹304.82 Cr. | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
| Dividends Paid | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹41.27 Cr. | DividendsPaidClassifiedAsFinancingActivities |
Every figure above is the exact value of the named XBRL element from MANKIND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).